1. Introduction {#sec1}
===============

Oxaliplatin and irinotecan are anticancer agents used to treat cancer patients \[[@B1], [@B2]\] and in colorectal cancer (CRC) patients, oxaliplatin-, and irinotecan-based therapy is generally used as first- or second-line treatment \[[@B3]--[@B6]\]. However, their treatment efficacy in advanced CRC patients is limited. Some types of bacteria mediate the resistance to gemcitabine in the pancreatic cancer cell line and to oxaliplatin but not to irinotecan in the colon cancer cell line \[[@B7]\]. A retrospective study revealed that antibiotics improve the treatment efficacy of gemcitabine-based therapy in advanced cancer patients \[[@B8]\]. We hypothesized that improvement in the treatment efficacy of cytotoxic anticancer agents by adding antibiotics is independent of the tumor primary site but dependent on the type of anticancer agent. This retrospective study assessed whether antibiotics improve the treatment efficacy of oxaliplatin-based but not irinotecan-based therapy in advanced CRC patients.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

The medical records (2011--2018) of patients diagnosed with CRC histopathologically and administered oxaliplatin- or irinotecan-based therapy as first- or second-line treatment were retrospectively reviewed at the Department of Medical Oncology, Tohoku University Hospital, Japan. Inclusion criteria were as follows: (1) patients with histologically confirmed colorectal adenocarcinoma, (2) patients with least one measurable cancer lesion, (3) patients with unresectable or metastatic lesions, (4) patients who underwent at least one course of oxaliplatin- or irinotecan-based therapy, and (5) patients in whom the treatment efficacy of oxaliplatin-or irinotecan-based therapy had been assessed by computed tomography (CT) at least once. Patients who did not met these inclusion criteria were excluded from the study.

Finally, we identified 120 patients who underwent oxaliplatin-based therapy and 100 patients who underwent irinotecan-based therapy. The oxaliplatin group was further subdivided into antibiotic-treated (group 1; *n* = 67) and antibiotic-untreated (group 2; *n* = 53) groups. Similarly, the irinotecan group was further subdivided into antibiotic-treated (group 1; *n* = 53) and antibiotic-untreated (group 2; *n* = 47) groups.

The study protocol was approved by the ethics committee of Tohoku University Hospital.

2.2. Treatment Methods {#sec2.2}
----------------------

The oxaliplatin-based therapy procedures in this study were as follows:mFOLFOX6: 85 mg/m^2^ of oxaliplatin and 200 mg/m^2^ of leucovorin given intravenously over 2 h, followed immediately by 400 mg/mg^2^ of a fluorouracil (5-FU) intravenous bolus and then 2400 mg/m^2^ of 5-FU as a 46 h infusionSOX: 80 mg/m^2^ of S-1 orally administered on days 1--14 and 130 mg/m^2^ of oxaliplatin given intravenously on day 1CapeOX: 1000 mg/^2^ of capecitabine orally administered twice a day on days 1--14 and 130 mg/m^2^ of oxaliplatin given intravenously on day 1

The irinotecan-based therapy procedures were as follows:mFOLFIRI: 150 mg/m^2^ of irinotecan and 200 mg/m^2^ of leucovorin given intravenously over 2 h, followed immediately by 400 mg/mg^2^ of a 5-FU intravenous bolus and then 2400 mg/m^2^ of 5-FU given as a 46 h infusionS-1 plus irinotecan: 80 mg/m^2^ of S-1 orally administered on days 1--14 and 125 mg/m^2^ of irinotecan given intravenously on day 1Irinotecan alone: 125 mg/m^2^ of irinotecan given twice a week intravenously

Both oxaliplatin group 1 and irinotecan group 1 were administered antibiotics from 2 weeks before the start of oxaliplatin- or irinotecan-based therapy, respectively, to the first imaging evaluation of the treatment efficacy of oxaliplatin- or irinotecan-based therapy, respectively, using CT.

2.3. Evaluation {#sec2.3}
---------------

Responses were assessed using the *Response Evaluation Criteria in Solid Tumors* version 1.0 \[[@B9]\]. The complete response (CR; all signs of cancer disappeared after oxaliplatin- or irinotecan-based therapy) and partial response (PR; ≥30% decrease in the diameter of measurable lesions on CT) rates were combined and defined as the response rate (RR). The CR, PR, and stable disease (SD; \<30% decrease and \<20% increase in the diameter of measurable lesions on CT) rates were combined and defined as the disease control rates (DCR). The relative dose intensity of oxaliplatin- or irinotecan was defined as the ratio of the total actual dose to the planned dose. Hematological toxicity was reviewed from medical records and evaluated according to the Common Terminology Criteria for Adverse Events version 4.0 \[[@B10]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

The median progression-free survival (PFS) and the median overall survival (OS) were calculated using the Kaplan--Meier method. *P* values of the RR and DCR between groups 1 and 2 were based on Fisher\'s exact test. Univariate and multivariate analyses were performed for the relationship between the response to oxaliplatin- or irinotecan-based therapy and the patients\' background and severe neutropenia. Statistical analyses, including univariate analysis, multivariate analysis, Pearson\'s chi-square test, and Fisher\'s exact test, were performed using JMP® 11 (SAS Institute Inc., Cary, NC, USA). *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

Patient characteristics are presented in [Table 1](#tab1){ref-type="table"}. The number of patients who underwent oxaliplatin-based therapy as first- or second-line treatment was comparable between groups 1 and 2. Similarly, the number of patients who underwent irinotecan-based therapy as first- or second-line treatment was comparable between groups 1 and 2. The number of patients who underwent surgery for their primary lesion was significantly high in oxaliplatin group 2 compared to group 1 ([Table 1](#tab1){ref-type="table"}). However, univariate and multivariate analysis showed that the imbalance in the ratio of patients who underwent surgery between oxaliplatin groups 1 and 2 does not influence the correlation between antibiotic treatment and the treatment efficacy of oxaliplatin-based therapy.

3.2. Efficacy of Oxaliplatin- or Irinotecan-Based Therapy {#sec3.2}
---------------------------------------------------------

The RR and DCR of both oxaliplatin and irinotecan groups 1 and 2 are given in [Table 2](#tab2){ref-type="table"}. Both RR and DCR were significantly high in oxaliplatin group 1 compared to oxaliplatin group 2. The RR of oxaliplatin groups 1 and 2 was 58.2% and 30.2%, respectively, while the DCR was 92.5% and 64.2%, respectively. In contrast, there was no significant difference in the RR and DCR between irinotecan groups 1 and 2. The RR of irinotecan groups 1 and 2 was 17.8% and 20.0%, respectively, while the DCR was 75.6% and 69.1%, respectively.

Both median PFS and median OS were significantly long in oxaliplatin group 1 compared to oxaliplatin group 2. As shown in [Figure 1(a)](#fig1){ref-type="fig"}, the median PFS of oxaliplatin groups 1 and 2 was 10.5 months (95% confidence interval \[CI\] = 7.5--12.2) and 7.0 months (95% CI = 5.1--9.1), respectively. As shown in [Figure 1(b)](#fig1){ref-type="fig"}, the median OS of oxaliplatin groups 1 and 2 was 23.8 months (95% CI = 17.9--26.0) and 17.4 months (95% CI = 13.1--24.9), respectively.

In contrast, there was no significant difference in the median PFS and median OS between irinotecan groups 1 and 2. As shown in [Figure 2(a)](#fig2){ref-type="fig"}, the median PFS of irinotecan groups 1 and 2 was 8.2 months (95%CI = 6.2--12.7) and 7.9 months (95% CI = 5.9--10.6), respectively. As shown in [Figure 2(b)](#fig2){ref-type="fig"}, the median OS of irinotecan groups 1 and 2 was 16.8 months (95% CI = 12.0--23.0) and 13.1 months (95% CI = 10.4--23.7), respectively.

We divided oxaliplatin groups 1 and 2 into two groups, respectively. In each group, patients who were treated with fluoropyrimidine intravenously were assigned to oxaliplatin-1-mFOLFOX6 group and oxaliplatin-2-mFOLFOX6 group. In each group, patients who were treated with fluoropyrimidine orally were assigned to oxaliplatin-1-SOX/CapeOX group and oxaliplatin-2-SOX/CapeOX group. We compared the response rate, median PFS and the median OS between oxaliplatin-1-mFOLFOX6 group and oxaliplatin-1-SOX/CapeOX group or between oxaliplatin-2-mFOLFOX6 group oxaliplatin-2-SOX/CapeOX group, respectively. As shown in Supplemental [Figure 1](#supplementary-material-1){ref-type="supplementary-material"} and Supplemental [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}, there was no significant difference in median PFS or median OS between oxaliplatin-1-mFOLFOX6 and oxaliplatin-1-SOX/CapeOX or between oxaliplatin-2-mFOLFOX6 group and oxaliplatin-2-SOX/CapeOX group, respectively.

As described in Supplemental [Table 1](#supplementary-material-1){ref-type="supplementary-material"}, there was no significant difference in response rate between oxaliplatin-1-mFOLFOX6 and oxaliplatin-1-SOX/CapeOX or between oxaliplatin-2-mFOLFOX6 group and oxaliplatin-2-SOX/CapeOX group, respectively.

3.3. Hematological Toxicity {#sec3.3}
---------------------------

Hematological toxicity values of both oxaliplatin and irinotecan groups 1 and 2 are given in [Table 3](#tab3){ref-type="table"}. The number of patients with severe leukopenia and neutropenia in oxaliplatin group 1 was significantly high compared to oxaliplatin group 2. The anemia and thrombocytopenia incidence rates and the increase in bilirubin, liver transaminase, and creatinine were similar in oxaliplatin groups 1 and 2. Similarly, the number of patients with severe leukopenia and neutropenia in irinotecan group 1 was significantly high compared to irinotecan group 2. The leukopenia, anemia, and thrombocytopenia incidence rates and the increase in bilirubin, transaminase, and creatinine were similar in irinotecan groups 1 and 2.

3.4. Univariate and Multivariate Analyses {#sec3.4}
-----------------------------------------

Results of univariate and multivariate analyses are shown in [Table 4](#tab4){ref-type="table"}. We found a statistically significant relationship between the response to oxaliplatin-based therapy and antibiotic treatment (univariate analysis: *P*=0.0159; multivariate analysis: *P*=0.0114). The other seven factors were not significantly correlated with the response to oxaliplatin-based therapy. In addition, all eight factors were not significantly correlated with the response to irinotecan-based therapy.

4. Discussion {#sec4}
=============

A previous study \[[@B7]\] revealed that a decrease in intratumor bacteria by antibiotic treatment augments the antitumor efficacy of gemcitabine in tumor-bearing mice. On the basis of that report \[[@B7]\], we retrospectively demonstrated that antibiotic treatment augments the treatment efficacy of gemcitabine-based therapy in advanced cancer patients \[[@B8]\]. In addition, a decrease in bacteria by adding antibiotics also augments the cytotoxicity of oxaliplatin but not of irinotecan in the CRC cell line *in vitro* \[[@B7]\], which is consistent with our results in this study. Antibiotic treatment is a factor that is significantly correlated with the efficacy of oxaliplatin-based therapy in advanced CRC patients.

Patients with leukopenia or neutropenia are generally administered antibiotics for prophylaxis \[[@B11]\]. Therefore, it is inevitable that a high number of advanced CRC patients administered antibiotics get leukopenia or neutropenia compared to advanced CRC patients not administered antibiotics. This seems to indicate that adding antibiotics to oxaliplatin- or irinotecan-based therapy does not increase cytotoxicity by oxaliplatin- or irinotecan-based therapy in advanced CRC patients. In addition, there seems to be no correlation between an increase in the incidence rate of leukopenia and improvement in the treatment efficacy of anticancer agents. However, it has been reported that 5-FU and oxaliplatin combination therapy for patients with advanced colorectal cancer has stronger myelotoxicity than SOX therapy or CapeOX therapy for patients with advanced colorectal cancer \[[@B12], [@B13]\]. There was a higher rate of patients who were treated with mFOLFOX6 regimen in oxaliplatin group 1 when compared to those in oxaliplatin group 2. This might be one explanation to the reason why there were a higher rate of leukopenia and neutropenia in oxaliplatin group 1 than in oxaliplatin group 2.

It has been reported that the primary resection of colorectal cancer worsens the prognosis of patients with advanced colorectal cancer \[[@B14]\]. There was a significantly higher resection rate of the primary site in oxaliplatin group 2 when compared to those in oxaliplatin group 1. The shorter overall survival time of oxaliplatin group 2 when compared to that of oxaliplatin group 1 might be partly attributable to the higher rate of the resection of the primary site in oxaliplatin group 2.

A previous study reported improvement in the treatment efficacy of anticancer agents by adding antibiotics in pancreatic cancer patients \[[@B8]\], indicating that this improvement is independent of the tumor primary site. In contrast, improvement in the treatment efficacy of anticancer agents by adding antibiotics seems to depend on the type of anticancer agent.

This study had a few limitations. First, the study had a retrospective design. Second, the number of patients included was relatively small. Third, cancer type studies were limited to CRC. Both gastric cancer and pancreatic cancer patients undergo oxaliplatin-based therapy in clinical practice \[[@B15], [@B16]\]. In addition, lung cancer, gastric cancer, and ovarian cancer patients undergo irinotecan-based therapy \[[@B2], [@B17], [@B18]\]. However, we did not assess the treatment efficacy and safety of adding antibiotics to oxaliplatin- or irinotecan-based therapy in patients with these types of cancer. Fourth, we could not obtain data on the incidence rate of nonhematological toxicities such as diarrhea. There are trillions of bacteria in the intestinal mucosa \[[@B19]\]. Antibiotic treatment decreases the number of bacteria in the intestinal mucosa and should augment the cytotoxicity of oxaliplatin in the intestinal mucosa, thereby increasing diarrhea. Fifth, we did not assess whether bacteria exist in tumor tissue pathologically in our patients. *Fusobacterium nucleatum*, which is part of the gut microbiome, is strongly associated with the tumorigenesis of CRC \[[@B20]\] and infiltrates cancer tissue in advanced CRC patients \[[@B21], [@B22]\]. It is possible that in a large proportion of our patients, bacteria infiltrated CRC tissue. Therefore, improvement in the treatment efficacy of oxaliplatin-based therapy might be attributable to a decrease in bacteria in tumor tissue by adding antibiotics. Further prospective or retrospective studies are required in order to overcome these limitations.

5. Conclusion {#sec5}
=============

Adding antibiotics is a potential therapeutic option to improve the treatment efficacy of oxaliplatin-based but not irinotecan-based therapy in advanced CRC patients. Prospective or retrospective studies to assess the treatment efficacy and safety of adding antibiotics to oxaliplatin- or irinotecan-based therapy are warranted.
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###### 

Supplemental Table 1: RRs and DCRs of intravenous fluoropyrimidine treatment group and oral fluoropyrimidine treatment group. Supplemental Figure 1: Kaplan--Meier curve of the (a) PFS and (b) OS of oxaliplatin-1-mFOLFOX6 group and oxaliplatin-1-SOX/CapeOX group. PFS: progression-free survival; OS: overall survival. Supplemental Figure 2: Kaplan--Meier curve of the (a) PFS and (b) OS of oxaliplatin-2-mFOLFOX6 group and oxaliplatin-2-SOX/CapeOX group. PFS: progression-free survival; OS: overall survival.

###### 

Click here for additional data file.

![Kaplan--Meier curve of the (a) PFS and (b) OS of antibiotic-treated group (group 1) and antibiotic-untreated group (group 2) in oxaliplatin-based therapy. PFS: progression-free survival; OS: overall survival.](JO2020-1701326.001){#fig1}

![Kaplan--Meier curve of the (a) PFS and (b) OS of the antibiotic-treated group (group 1) and antibiotic-untreated group (group 2) in irinotecan-based therapy. PFS: progression-free survival; OS: overall survival.](JO2020-1701326.002){#fig2}

###### 

Background of patients who underwent oxaliplatin- or irinotecan-based therapy (*n* = 220).

  Group                                                        Oxaliplatin    *P*            Irinotecan   *P*                           
  ------------------------------------------------------------ -------------- -------------- ------------ -------------- -------------- --------
  Number                                                       67             53                          53             47              
  Sex                                                                                                                                   
   Male                                                        38 (56.7)      29 (54.7)      0.9901       33 (62.2)      26 (55.3)      0.481
   Female                                                      29 (43.3)      24 (45.3)                   20 (37.8)      21 (44.7)       
  Age (mean)                                                   68 (27--86)    66 (24--83)                 70 (32--80)    66 (38--83)     
  Kras status                                                                                                                           
   Wild type                                                   35 (52.2)      28 (52.8)      0.6653       22 (41.5)      26 (55.3)      0.1677
   Mutant type                                                 32 (48.8)      25 (47.2)                   31 (58.5)      21 (44.7)       
  Line of oxaliplatin-based or irinotecan-based chemotherapy                                                                            
   First line                                                  45 (67.1)      36 (67.9)      0.7569       21 (39.6)      15 (31.9)      0.4229
   Second-line                                                 22 (32.8)      17 (32.1)                   32 (60.4)      32 (68.1)       
  Primary site                                                                                                                          
   Left side colon                                             48 (71.6)      30 (56.6)      0.1314       31 (58.5)      33 (70.2)      0.2229
   Right side colon                                            19 (28.4)      23 (43.4)                   22 (41.5)      14 (29.8)       
   Relative dose intensity of oxaliplatin (%)                  72.1           71.3                        69.4           65.8            
  Resection of primary site                                                                                                             
   (+)                                                         39 (58.2)      47 (88.7)      0.002        37 (69.8)      36 (76.6)      0.4456
   (−)                                                         28 (41.8)      6 (11.3)                    16 (30.2)      11 (23.4)       
  Regimen of first-line chemotherapy (%)                                                                                                
   FOLFOX (plus bmab or cmab or pmab)                          53 (79.1)      33 (62.3)      0.0521                                      
   SOX (plus bmab)                                             9 (13.4)       12 (22.6)      0.1874                                      
   CapeOX (plus bmab)                                          5 (7.5)        8 (16.9)       0.1816                                      
   FOLFORI (plus bmab or rmab or AFL or cmab or pmab)                                                     38 (71.7)      32 (68.1)      0.6939
   S-1 plus irinotecan                                                                                    13 (24.5)      13 (27.7)      0.7216
   CPT11                                                                                                  2 (3.8)        2 (4.3)        0.9023
  Average number of treatment (range)                                                                                                   
   FOLFOX (plus bmab or cmab or pmab)                          17.1 (4--28)   18.9 (6--29)                                               
   SOX (plus bmab)                                             10.5 (4--14)   11.2 (5--13)                                               
   CapeOX (plus bmab)                                          9.5 (3--12)    10.1 (4--13)                                               
   FOLFORI (plus bmab or rmab or AFL or cmab or pmab)                                                     16.9 (5--22)   15.8 (4--23)    
   S-1 plus irinotecan                                                                                    10.5 (4--16)   11.8 (5--15)    
   CPT11                                                                                                  16.2 (5--18)   15.8 (4--21)    
  Postchemotherapy                                                                                                                      
   Irinotecan-based chemotherapy                               35 (52.2)      27 (50.9)      0.8879       0 (0)          0 (0)          1
   Oxaliplatin-based chemotherapy                              0 (0)          0 (0)          1            21 (39.6)      15 (31.9)      0.4229
   Cmab or pmab plus irinotecan                                7 (10.4)       5 (9.4)        0.9011       5 (9.4)        4 (8.5)        0.8854
   Trifluridine, tipiracil                                     19 (28.4)      15 (28.3)      0.9946       21 (39.6)      14 (29.8)      0.3034
   Regorafenib                                                 12 (17.9)      11 (20.8)      0.6943       12 (22.6)      13 (27.7)      0.563
   Trastuzumab                                                 1 (1.5)        0 (0.0)        0.3718       1 (1.9)        0 (0.0)        0.3439
   Pembrolizumab                                               1 (1.5)        0 (0.0)        0.3718       1 (1.9)        0 (0.0)        0.3439

FOLFOX: fluorouracil (5-FU) plus oxaliplatin combination therapy; SOX: S-1 plus oxaliplatin combination therapy; CapeOX: capecitabine plus oxaliplatin combination therapy; Bmab: bevacizumab. *P* was calculated using Pearson\'s chi-square test.

###### 

RRs and DCRs of antibiotic-treated and antibiotic-untreated groups in oxaliplatin- and irinotecan-based therapy.

  Group     Oxaliplatin   Irinotecan                          
  --------- ------------- ------------ -------- ------ ------ --------
  CR        0             0                     0      0       
  PR        39            19                    11     8       
  SD        23            21                    27     26      
  PD        5             13                    17     11      
  RR (%)    58.2          30.2         0.0224   20.8   17     0.7778
  DCR (%)   92.5          64.2         0.0201   71.7   72.3   0.6724

CR: complete response; PR: partial response; SD, stable disease; PD: progressive disease; RR: response rate; DCR: disease control rate. *P* was calculated using Fisher\'s exact test.

###### 

Hematological toxicity of antibiotic-treated and antibiotic-untreated groups in oxaliplatin- and irinotecan-based therapy.

  Group                     Oxaliplatin-based therapy   Irinotecan-based therapy                                  
  ------------------------- --------------------------- -------------------------- ------- ----------- ---------- -------
  Leukopenia                9 (13.4)                    1 (1.9)                    0.042   11 (20.8)   5 (10.6)   0.156
  Neutropenia               22 (32.8)                   5 (9.4)                    0.016   20 (37.7)   6 (12.8)   0.045
  Anemia                    7 (10.4)                    5 (9.4)                    0.854   2 (3.8)     2 (4.3)    0.751
  Thrombocytopenia          3 (4.5)                     5 (9.4)                    0.281   5 (9.4)     4 (8.5)    0.881
  Elevation of bilirubin    2 (3.0)                     2 (3.8)                    0.812   2 (3.8)     1 (2.1)    0.564
  Elevation of AST or ALT   7 (10.4)                    5 (9.4)                    0.854   5 (9.4)     6 (12.8)   0.441
  Elevation of creatinine   0 (0.0)                     1 (1.9)                    0.2     0 (0.0)     0 (0.0)    1

ALT: alanine aminotransferase; AST: aspartate aminotransferase. *P* was calculated using Pearson\'s chi-square test.

###### 

Univariate and multivariate analyses of the relationship between the response to oxaliplatin- or irinotecan-based therapy and the patients\' background and severe neutropenia.

                                      *n* (%)     Oxaliplatin-based therapy                          Irinotecan-based therapy                                    
  ----------------------------------- ----------- --------------------------- ---------------------- -------------------------- -------- ----------------------- --------
  Sex                                                                                                                                                            
   Male                               67 (55.8)   0.611                       1.81 (0.722--3.1222)   0.5896                     0.8222   1.352 (0.745--3.089)    0.7856
   Female                             53 (44.2)                                                                                                                   
  Age                                                                                                                                                            
   ≧65                                68 (56.7)   0.249                       1.861 (0.822--2.156)   0.3902                     0.3389   1.698 (0.722--1.899)    0.4256
   \<65                               52 (43.3)                                                                                                                   
  Antibiotics                                                                                                                                                    
   Untreated                          53 (44.2)   0.0159                      2.815 (1.656--7.228)   0.0155                     0.5439   1.7989 (0.754--2.156)   0.6001
   Treated                            67 (55.8)                                                                                                                   
  Line of chemotherapy                                                                                                                                           
   First line                         81 (67.5)   0.4489                      1.525 (0.758--2.115)   0.4998                     0.5668   1.554 (0.564--2.225)    0.7054
   Second-line                        39 (32.5)                                                                                                                   
  Severe (grade 3 or 4) neutropenia                                                                                                                              
   Negative                           93 (77.5)   0.5564                      0.789 (0.252--2.355)   0.4655                     0.6612   1.882 (0.711--2.225)    0.5154
   Positive                           27 (22.5)                                                                                                                   
  Operation history                                                                                                                                              
   Negative                           34 (28.3)   0.191                       0.289 (0.896--6.283)   0.174                      0.311    0.7988 (0.315--8.256)   0.3598
   Positive                           86 (71.7)                                                                                                                   
  Ras status                                                                                                                                                     
   Wild type                          63 (52.5)   0.8406                      1.458 (0.787--1.552)   0.7154                     0.7723   1.615 (0.498--2.125)    0.782
   Mutant type                        57 (47.5)                                                                                                                   
  Cancer primary site                                                                                                                                            
   Right side colon                   42 (35.0)   0.721                       0.778 (0.324--2.336)   0.747                      0.6129   0.756 (0.225--3.089)    0.7255
   Left side colon                    78 (65.0)                                                                                                                   

OR: odds ratio; CI: confidence interval. *P* was calculated using Pearson\'s chi-square test.
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